REFERENCES
1. Institute for Health Metrics and Evaluation. GBD Compare. IHME, University of Washington; 2015.
2. Martin WJ, Glass RI, Balbus JM, Collins FS. A major environmental cause of death.
Science. 2011;334:180-181.3. Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186:155-161.
4. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med. 2002;166:675-679.
5. Anthonisen NR. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;142:233.
6. Abukhalaf J, Davidson R, Villalobos N, et al. Chronic obstructive pulmonary disease mortality, a competing risk analysis. Clin Respir J. 2018;12:2598-2605.
7. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. NEngl J Med. 2004;350:1005- 1012.
8. Espantoso-Romero M, Roman Rodriguez M, Duarte-Perez A, et al. External validation of multidimensional prognostic indices (ADO, BODEx and DOSE) in a primary care international cohort (PROEPOC/COPD cohort). BMC Pulm Med. 2016;16:143.
9. Lowe KE, Regan EA, Anzueto A, et al. COPDGene® 2019: redefining the diagnosis of chronic obstructive pulmonary disease. Chronic Obstr Pulm Dis. 2019;6:384-399.
10. Lichtenstein DA, Meziere GA. The BLUE-points: three standardized points used in the BLUEprotocol for ultrasound assessment of the lung in acute respiratory failure. Crit Ultrasound J. 2011;3:109-110.
11. Hall JB, Kress J, Schmidt GA. Principles of Critical Care. 4th ed. McGraw-Hill Education; 2015.
12. Chapman KR, Burdon JGW, Piitulainen E, et al. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo- controlled trial.
Lancet. 2015;386:360-368.13. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. NEngl J Med. 2008;359:1543-1554.
14. Lasserson TJ, Ferrara G, Casali L. Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. Cochrane Database Syst Rev. 2011;(12):CD004106.
15. Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in
patients with COPD. NEngl JMed. 2018;378:1671-1680.
16. Chalmers JD, Laska IF, Franssen FME, et al. Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline. Eur Respir J 2020;55:2000351.
17. Criner GJ, Cordova F, Sternberg AL, Martinez FJ. The National Emphysema Treatment Trial (NETT): part I - lessons learned about emphysema. Am J Respir Crit Care Med. 2011;184:763- 770.
18. Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014—an update from the Pulmonary Transplantation Council of the International Society for heart and lung transplantation. J Heart Lung Transplant. 2015;34:1-15.
19. Eskander A, Waddell TK, Faughnan ME, Chowdhury N, Singer LG. BODE index and quality of life in advanced chronic obstructive pulmonary disease before and after lung transplantation. J Heart Lung Transplant 2011;30:1334-1341.
20. Valapour M, Lehr CJ, Skeans MA, et al. OPTN/SRTR 2018 annual data report: lung. Am J Transplant. 2020;20:427-508.
21. Casaburi R, ZuWallack R. Pulmonary rehabilitation for management of chronic obstructive pulmonary disease. NEngl Journal Med. 2009;360:1329-1335.
22. Group TL-TOTTR. A randomized trial of long-term oxygen for COPD with moderate desaturation. NEngl J Med. 2016;375:1617-1627.
23. Lacasse Y, Series F, Corbeil F, et al. Randomized trial of nocturnal oxygen in chronic obstructive pulmonary disease. NEngl J Med. 2020;383:1129-1138.
24. Murphy PB, Rehal S, Arbane G, et al.
Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. JAMA. 2017;317:2177-2186.25. Kohnlein T, Windisch W, Kohler D, et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. Lancet Respir Med. 2014;2:698-705.
26. Pison CM, Cano NJ, Cherion C, et al. Multimodal nutritional rehabilitation improves clinical outcomes of malnourished patients with chronic respiratory failure: a randomised controlled trial. Thorax. 2011;66:953-960.
27. Aberle DR, Adams AM; National Lung Screening Trial Research Team, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. NEngl JMed. 2011;365:395-409.
28. Cosentino J, Zhao H, Hardin M, et al. Analysis of asthma-chronic obstructive pulmonary disease overlap syndrome defined on the basis of bronchodilator response and degree of emphysema. Ann Am Thorac Soc. 2016;13:1483-1489.
29. Walters JA, Tang JNQ, Poole P, Wood-Baker R. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017;1:CD001390.
30. Centers for Disease Control and Prevention. Recommended Adult Immunization Schedule for ages 19 years or older 2021. Accessed May 9, 2021. Available at https://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf.
31. Lee SC, Son KJ, Han CH, Park SC, Jung JY. Impact of COPD on COVID-19 prognosis: a nationwide population-based study in South Korea. Sci Rep. 2021;11:3735.
32. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl JMed. 2011;365:689-698.
33. Martinez FJ, Calverley PMA, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
Lancet. 2015;385:857- 866.34. Stoller JK, Aboussouan LS. A review of α1-antitrypsin deficiency. Am J Respir Crit Care Med. 2012;185:246-259.
35. Aaron SD, Fergusson D, Marks GB, et al. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. Thorax. 2008;63:122-128.
36. Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013;309:2223-2231.
37. Rizkallah J, Man SFP, Sin DD. Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis. Chest. 2009;135:786-793.
38. Braman SS. The global burden of asthma. Chest. 2006;130:4S-12S.
39. Shanawani H. Health disparities and differences in asthma: concepts and controversies. Clin Chest Med. 2006;27:17-28, v.
40. Cloutier MM, Baptist AP; Expert Panel Working Group of the National Heart, Lung, and Blood Institute(NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC), et al. 2020 Focused updates to the asthma management guidelines: a report from the National asthma education and prevention program coordinating committee expert panel working group. J Allergy Clin Immunol 2020;146:1217-1270.
41. O’Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. NEngl J Med. 2018;378:1865-1876.
42. Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;(1):CD003559.
43. Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3:355-366.
44. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198-1207.
45. Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of Benralizumab in severe asthma. NEngl JMed. 2017;376:2448-2458.
46. Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. NEngl JMed. 2018;378:2486-2496.
47. Valli G, Paoletti P, Savi D, Martolini D, Palange P. Clinical use of Heliox in asthma and COPD. Monaldi Arch Chest Dis. 2007;67:159-164.
48. Althoff MD, Holguin F, Yang F, et al. Noninvasive ventilation use in critically ill patients with acute asthma exacerbations. Am J Respir Crit Care Med. 2020;202:1520-1530.
49. Nelson HS, Weiss ST, Bleecker ER, et al. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129(1):15-26.